Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Coal tar

This article was originally published in The Tan Sheet

Executive Summary

Presence of cancer warnings on some dandruff, psoriasis OTCs "may render the products misbranded," and FDA is "evaluating the complex issues raised" by such warnings, agency says in recent letter to Alva-Amco counsel Bell, Boyd & Lloyd (Chicago). Law firm had requested FDA determine whether Prop 65 cancer warnings found on some OTC coal tar medications - including Alva-Amco's Psoriasin Gel, GlaxoSmithKline/Block Drug's Tegrin, Medtech's Oxipor - constitute misbranding. Agency's February decision that additional warnings are not required on such products did not address whether inclusion of Prop 65 statement would misbrand them (1"The Tan Sheet" March 5, p. 4). Prop 65 lawsuit against Alva-Amco, other coal tar product makers slated for trial in January...

You may also be interested in...

OTC Coal Tar Skin Cancer Causation Data Lacking - FDA

The future of California Proposition 65 litigation against manufacturers, distributors and retailers of coal tar-containing dandruff shampoos, soaps and ointments could become clearer at a March 16 status conference in San Francisco state court.

Takeda Acquires Celiac Venture PvP For Up To $330m

Japanese firm exercises option after promising Phase I results in disorder with no approved drugs, in deal that builds out its celiac pipeline.

QUOTED. 26 February 2020. Mark Leahey.

In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts